TO: Australian Stock Exchange Ltd Company Announcements Office FROM: C E Pizzey, Company Secretary DATE: 11 April 2005 RE: VISION BIOSYSTEMS ANNOUNCES CORPORATE AGREEMENT WITH AMERIPATH FOR PLACEMENT OF BOND STAINING SYSTEMS CONTENTS OF ANNOUNCEMENT Vision Systems’ subsidiary, Vision BioSystems, today announced a corporate agreement with Ameripath, Inc. for the placement of Bond staining systems and associated reagents, as well as other instrumentation products such as the Peloris rapid tissue processor. Ameripath is one of the leading anatomical pathology practices in the United States. “Ameripath is a market leader in the field of anatomical pathology with an extensive laboratory network that is committed to delivering excellence in service to its customers. We are very proud to be able to work with an organisation such as Ameripath as they strive to further enhance service levels and quality”, states Michael Ohanessian, Chief Executive of Vision BioSystems. Vision BioSystems develops, manufactures and distributes instruments and reagents to clinical histopathology and research laboratories worldwide. Vision’s products are used for tissue preparation and staining to assist with the diagnosis of cancer and infectious diseases. C E Pizzey Company Secretary For further information, contact Dr James Fox Mr C Euan Pizzey Managing Director Director of Finance Vision Systems Limited Vision Systems Limited Telephone: 61 3 9211 7018 Telephone: 61 3 9211 7020 Facsimile: 61 3 9211 7001 Facsimile: 61 3 9211 7001
VSL Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
